IP Library Granted Patent US 7,795,448
Granted Patent B2
US 7,795,448 · App. 11/124,608 · Granted Sep 14, 2010

Imidazoyl-benzamide anti-cancer agents

Assignee: Cytokinetics, Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,795,448
App. No.
11/124,608
Granted
Sep 14, 2010
Kind
B2
Abstract

Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders.

Claims (54)

1. A compound of Formula V

or a pharmaceutically acceptable salt thereof, wherein

R 2 is hydrogen or lower alkyl;

R 3 is lower alkyl substituted with a hydroxyl or a phosphate ester thereof;

R 11 is hydrogen, cyano, nitro, or halo; sulfonyl

R 12 is lower alkoxy or 2,2,2-trifluoro-1-methyl-ethoxy;

R 13 is hydrogen;

R 14 is 1H-imidazol-2-yl, pyrazol-3-yl, or 1H-imidazol-4-yl, each of which is optionally substituted with one, two, or three groups chosen from lower alkyl, halo, acyl, sulfonyl, cyano, nitro, amino, heteroaryl, trifluoromethyl, trifluoroethyl, lower alkyl substituted with hydroxy or lower alkoxy, and lower alkyl substituted with an amino group wherein the amino group is further optionally substituted with a lower alkyl group and/or a group —C(O)R b wherein R b is chosen from hydrogen, lower alkoxy, amino, (lower alkyl)amino, di-(lower alkyl)amino, C 1 -C 6 alkyl, aryl, and heteroaryl; and

R 15 is chosen from hydrogen, halo, hydroxyl, and lower alkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 15 is hydrogen.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 11 is chloro or cyano.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 12 is propoxy or 2,2,2-trifluoro-1-methyl-ethoxy.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen.

6. A composition comprising a pharmaceutical excipient and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 14 is chosen from 1H-imidazol-2-yl, and 1H-imidazol-4-yl, each of which is optionally substituted with one or two groups chosen from lower alkyl, lower alkyl substituted with hydroxy, and lower alkyl substituted with an amino group wherein the amino group is further substituted with a group —C(O)R b wherein R b is C 1 -C 6 alkyl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 14 is chosen from

2-(1-Acetylamino-ethyl)-1-ethyl-1H-imidazol-4-yl;

2-acetyl-1-ethyl-1H-imidazol-4-yl;

2-(1-Acetylamino-propyl)-1-ethyl-1H-imidazol-4-yl;

2-(1-Acetylamino-ethyl)-1-ethyl-1H-imidazol-4-yl;

2-[1-(Acetyl-methyl-amino)-ethyl]-1-ethyl-1H-imidazol-4-yl;

2-(1-Acetylamino-ethyl)-1-propyl-1H-imidazol-4-yl;

2-(1-Acetylamino-ethyl)-1-ethyl-1H-imidazol-4-yl;

2-[1-(3-methyl-ureido)-ethyl]-1-ethyl-1H-imidazol-4-yl;

2-(1-Acetylamino-ethyl)-1-isopropyl-1H-imidazol-4-yl

2-(1-Acetylamino-2-methyl-propyl)-1-ethyl-1H-imidazol-4-yl;

2-(1-(isopropoxycarbonylamino)-ethyl)-1-ethyl-1H-imidazol-4-yl;

2-(1-formylamino-ethyl)-1-ethyl-1H-imidazol-4-yl;

2-(1-methyl-1-hydroxy-ethyl)-1-ethyl-1H-imidazol-4-yl;

2-acetyl-1-(3-hydroxypropyl)-1H-imidazol-4-yl;

2-t-butyl-1-ethyl-1H-imidazol-4-yl;

2-t-butyl-1-methyl-1H-imidazol-4-yl;

2-acetyl-1-methyl-1H-imidazol-4-yl;

2-isobutyryl-1-methyl-1H-imidazol-4-yl;

2-acetyl-1-(2-hydroxy-ethyl)-1H-imidazol-4-yl;

2-(1-methyl-1-hydroxy-ethyl)-1-ethyl-1H-imidazol-4-yl;

2-(3-hydroxy-pent-3-yl)-1-ethyl-1H-imidazol-4-yl;

2-(1-hydroxy-1-methyl-ethyl)-1-(2,2,2-trifluoroethyl)-1H-imidazol-4-yl;

2-acetyl-1-(2-methoxyethyl)-1H-imidazol-4-yl;

2-acetyl-1-propyl-1H-imidazol-4-yl;

2-(1-hydroxy-2-methyl-propyl)-1-ethyl-1H-imidazol-4-yl;

2-(1-hydroxy-1-methyl-ethyl)-1-ethyl-1H-imidazol-4-yl;

2-propionyl-1-methyl-1H-imidazol-4-yl;

2-(1-hydroxy-1-methyl-ethyl)-1-(2,2,2-trifluoroethyl)-1H-imidazol-4-yl;

2-(1-formylamino-ethyl)-1-methyl-1H-imidazol-4-yl;

2-(1-hydroxy-1-methyl-ethyl)-1-methyl-1H-imidazol-4-yl;

2-(1-acetylamino-ethyl)-1-methyl-1H-imidazol-4-yl;

2-(1-hydroxy-1-methyl-ethyl)-1-ethyl-1H-imidazol-4-yl; and

2-(3-hydroxy-pent-3-yl)-1-ethyl-1H-imidazol-4-yl.

9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 14 is chosen from

2-(1-Acetylamino-ethyl)-1-ethyl-1H-imidazol-4-yl;

2-(1-methyl-1-hydroxy-ethyl)-1-ethyl-1H-imidazol-4-yl; and

2-(1-hydroxy-1-methyl-ethyl)-1-methyl-1H-imidazol-4-yl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is —CH 2 CH 2 OH.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2010
From: GLAXOSMITHKLINE LLC
To: CYTOKINETICS, INCORPORATED
Reel/Frame 024211/0909 →
CHANGE OF NAME Recorded Mar 29, 2010
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 024140/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2006
From: DUFFY, KEVIN; FITCH, DUKE; TEDESCO, ROSANNA
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 018585/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2005
From: DHANAK, DASHYANT; KNIGHT, STEVEN D.; ADAMS, NICHOLAS D.; PARRISH, CYNTHIA A.
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 016811/0251 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2005
From: QIAN, XIANGPING; ZHOU, HAN-JIE; ASHCRAFT, LUKE W.; YAO, BING; JIANG, HONG; HUANG, JENNIFER KUO CHEN; WANG, JIANCHAO; MORGANS, JR., DAVID J.; MORGAN, BRADLEY PAUL; BERGNES, GUSTAVE
To: CYTOKINETICS, INC.
Reel/Frame 016811/0259 →
Continuity (3)
Continuation In Part 1112170900 · May 3, 2005
Provisional Application 6056951000 · May 6, 2004
Related Publication 20070197481A1 · Aug 23, 2007